1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United Kingdom >
  5. Scantox Acquires Gentronix

M&A Deal Summary

Scantox Acquires Gentronix

On September 9, 2024, Scantox acquired life science company Gentronix

Acquisition Highlights
  • This is Scantox’s 2nd transaction in the Life Science sector.
  • This is Scantox’s 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2024-09-09
Target Gentronix
Sector Life Science
Buyer(s) Scantox
Deal Type Add-on Acquisition

Target

Gentronix

Cheshire, United Kingdom
Gentronix is a biotechnology company helping to accelerate the pace of drug discovery in the pharmaceutical industry. Its first product, called GreenScreen, is a novel pre-regulatory screening assay for use at the hits-to-lead and early lead optimization stages of the drug discovery process. GreenScreen is based in Cheshire, United Kingdom.

Search 215,058 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Scantox

Lille Skensved, Denmark
Category Company
Founded 1977
Sector Life Science
Employees70
Revenue 109M DKK (2019)
DESCRIPTION

Scantox is a GLP (“Good Laboratory Practice”) accredited CRO, providing pre-clinical research services, including regulatory in-vivo toxicology studies, that are critical to any drug development process. Scantox was founded in 1977 and is based in Lille Skensved, Denmark.

DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Add-on Acquisition M&A Deals 1 of 1
Country: United Kingdom M&A 1 of 1
Year: 2024 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-11-30 Scantox Neuro

Grambach, Austria

Scantox Neuro specializes in neurodegenerative, rare diseases and mental disorders. Scantox Neuro was founded in 1999 and is based in Grambach, Austria.

Buy -
Mergr

Solution for

Product

Company

Legal